Elite *Journal of Scientific Research and Review*. Volume 2 Issue 5(2024), Pp. 25-33
https://epjournals.com/journals/EJSRR

Role of HbF in Modulating Vaso-Occlusive Phenomena in Sickle Cell Anemia

[*]Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda.

[*]Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Sickle cell anemia (SCA) is a genetic hematological disorder characterized by the presence of abnormal hemoglobin, leading to the formation of sickled red blood cells (RBCs) and resultant vaso-occlusive crises (VOC). Fetal hemoglobin (HbF), a normal component of hemoglobin in fetal life, has been shown to exert a protective effect in individuals with SCA. This review examines the role of HbF in modulating vaso-occlusive phenomena in sickle cell anemia, highlighting the mechanisms through which HbF influences red blood cell deformability, blood viscosity, and inflammatory responses. Higher levels of HbF in the blood significantly reduce sickle polymerization, enhancing the deformability of RBCs and decreasing blood viscosity, which ultimately improves microvascular blood flow. Additionally, HbF exhibits anti-inflammatory properties that may help mitigate the inflammatory response associated with vaso-occlusive crises. Understanding these mechanisms is essential for developing therapeutic strategies aimed at increasing HbF levels to prevent VOC and improve patient outcomes.

Keywords: *Hemoglobin F, HbF, vaso-occlusive crisis, sickle cell anemia, fetal hemoglobin, red blood cells, hemorheology, therapeutic strategies.*

Introduction

Sickle cell anemia (SCA) is a genetic blood disorder caused by a mutation in the β-globin gene, resulting in the production of hemoglobin S (HbS), which polymerizes under low oxygen conditions. This polymerization leads to the deformation of red blood cells (RBCs) into a characteristic sickle shape, which impairs their flexibility and causes them to become trapped in small blood vessels. The resultant vaso-occlusive crises (VOC) are the hallmark of the disease, leading to severe pain, organ damage, and a significant decrease in the quality of life for affected individuals. Understanding the mechanisms that underlie the pathophysiology of SCA is critical for developing effective therapeutic strategies.[1-5] Fetal hemoglobin (HbF), composed of two alpha and two gamma chains, is the predominant hemoglobin during fetal development. It plays a vital role in oxygen transport and is known to possess unique properties that differentiate it from adult hemoglobin (HbA) and HbS. Notably, the presence of HbF has been associated with a reduced severity of sickle cell disease. Individuals with higher levels of HbF tend to experience fewer and less severe VOC, highlighting the potential protective effects of HbF in modulating sickle cell pathology.[6-10] The protective role of HbF in SCA is multifaceted. First, HbF can inhibit the polymerization of HbS, thereby reducing the likelihood of sickling under low-oxygen conditions. This inhibition is primarily due to the lower concentration of HbS in RBCs containing HbF. As a result, individuals with increased HbF levels often exhibit enhanced red blood cell deformability, which is crucial for maintaining blood flow in the microcirculation. Improved deformability allows

RBCs to traverse narrow capillaries more easily, reducing the risk of vaso-occlusion. Additionally, HbF has been shown to influence the hemorheological properties of blood. Higher HbF levels can decrease blood viscosity, a critical factor in the pathogenesis of VOC. Elevated blood viscosity increases the likelihood of red blood cell aggregation and impairs microvascular flow, contributing to the occurrence of vaso-occlusive events. By lowering blood viscosity, HbF may help improve overall blood flow dynamics and mitigate the risks associated with sickle cell disease.[11-15]

Chronic inflammation is another characteristic of sickle cell disease that plays a role in the pathogenesis of VOC. The inflammatory response is triggered by multiple factors, including hemolysis of sickled cells and endothelial activation. Research indicates that HbF may possess anti-inflammatory properties, helping to modulate the inflammatory response associated with sickle cell disease. By reducing the levels of pro-inflammatory cytokines and influencing leukocyte adhesion, HbF could contribute to a more favorable vascular environment, further protecting against VOC. Current therapeutic strategies to increase HbF levels have gained attention as a means to improve outcomes in individuals with sickle cell disease. Hydroxyurea, a cornerstone therapy for SCA, has been shown to effectively increase HbF production. By stimulating the synthesis of fetal hemoglobin, hydroxyurea reduces the proportion of sickled cells in circulation and has been associated with a decrease in the frequency of vaso-occlusive crises. Clinical studies have demonstrated the efficacy of hydroxyurea in reducing pain episodes, acute chest syndrome, and the need for blood transfusions in patients with SCD.[16-20] In addition to hydroxyurea, other therapeutic approaches are being investigated to increase HbF levels in sickle cell disease. Blood transfusion therapy can elevate HbF levels by introducing normal red blood cells into circulation, thereby reducing the sickled cell percentage. However, this approach carries the risk of iron overload and other transfusion-related complications, necessitating careful monitoring and management.[21-23]

The Mechanisms of HbF Modulation

The protective role of fetal hemoglobin (HbF) in sickle cell anemia (SCA) is attributed to several mechanisms that collectively contribute to the modulation of vaso-occlusive phenomena. This section discusses the key mechanisms through which HbF influences red blood cell (RBC) behavior, hemorheology, and inflammatory responses, thereby mitigating the risk of vaso-occlusion. One of the primary mechanisms through which HbF exerts its protective effects is the inhibition of HbS polymerization. Under low-oxygen conditions, HbS molecules tend to polymerize, leading to the formation of rigid structures that distort RBCs into a sickle shape. The presence of HbF competes with HbS for binding sites, effectively reducing the concentration of HbS in sickle cell RBCs. Studies have shown that even low levels of HbF can significantly decrease the likelihood of HbS polymerization, thereby preventing the sickling process. As a result, individuals with higher HbF levels tend to have a reduced number of sickled cells, contributing to improved blood flow and a lower incidence of vaso-occlusive crises.[24-28] HbF is associated with improved RBC deformability, a critical factor in maintaining normal blood flow, particularly in the microcirculation. Sickled RBCs have reduced flexibility and are more prone to obstructing small blood vessels, leading to ischemia and pain. However, the presence of HbF enhances the overall mechanical properties of RBCs, allowing them to deform more readily as they traverse narrow capillaries. Enhanced deformability is crucial for preventing vaso-occlusion, as it enables RBCs to adapt to varying vessel diameters and flow conditions. The increased presence of HbF in the RBC membrane improves membrane stability and integrity, further

supporting RBC flexibility and overall circulation.[29-33] Higher levels of HbF significantly influence the hemorheological properties of blood, particularly by reducing blood viscosity. In sickle cell disease, elevated blood viscosity is a major contributor to the risk of vaso-occlusion, as it promotes red blood cell aggregation and impedes blood flow. HbF's structural characteristics help decrease the overall viscosity of blood, making it easier for RBCs to circulate and reducing the likelihood of blockages in small vessels. By improving the fluidity of blood, HbF can enhance overall microvascular perfusion and reduce the incidence of vaso-occlusive events.[34-38]

Chronic inflammation is a prominent feature of sickle cell disease and plays a significant role in the pathogenesis of vaso-occlusive crises. The inflammatory process is triggered by hemolysis of sickled cells, endothelial injury, and the release of pro-inflammatory cytokines. HbF has been shown to possess anti-inflammatory properties, which may help mitigate the inflammatory response associated with SCA. Elevated HbF levels can reduce the secretion of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukins (IL-1, IL-6), thereby attenuating the overall inflammatory milieu. Additionally, HbF may influence leukocyte adhesion and activation, further contributing to a more favorable vascular environment.[39-43] Nitric oxide (NO) is a crucial signaling molecule involved in maintaining vascular tone and promoting blood flow. In sickle cell disease, oxidative stress and inflammation can lead to decreased NO bioavailability, exacerbating vascular dysfunction and promoting vaso-occlusive events. HbF may enhance the bioavailability of NO by reducing oxidative stress and improving endothelial function. This increase in NO availability can lead to vasodilation and improved blood flow, further decreasing the likelihood of vaso-occlusion.[46-49] The interactions between sickled RBCs and the vascular endothelium are critical in the development of vaso-occlusive phenomena. Increased adhesion of sickled cells to endothelial cells contributes to the obstruction of blood flow and the initiation of inflammatory responses. HbF's presence in RBCs may alter the adhesion properties of sickled cells, reducing their affinity for the endothelium. This modulation of endothelial interactions can help decrease the risk of microvascular obstruction and promote better blood flow.[50-52] In individuals with SCA, the presence of HbF can influence the production of erythroid progenitor cells, promoting the generation of more functional and less sickle-prone RBCs. By enhancing the pool of HbF-producing erythroid cells, the body can effectively counterbalance the adverse effects of sickle hemoglobin, leading to a more favorable clinical outcome. The transition from fetal to adult hemoglobin during development is a tightly regulated process known as the hemoglobin switch. Factors that influence this switch, including transcription factors and epigenetic modifications, can affect HbF levels in adults with sickle cell disease. Genetic factors, including single nucleotide polymorphisms (SNPs) and variations in regulatory elements, play a significant role in determining HbF levels in individuals with sickle cell disease. Additionally, epigenetic modifications, such as DNA methylation and histone acetylation, can influence the expression of fetal hemoglobin.[53-57]

Therapeutic Strategies to Increase HbF Levels

Increasing fetal hemoglobin (HbF) levels in individuals with sickle cell anemia (SCA) has emerged as a promising therapeutic strategy to mitigate the complications associated with the disease, particularly vaso-occlusive crises (VOC). Several approaches have been developed or are currently under investigation to enhance HbF production, each with distinct mechanisms and potential benefits. This section explores the key therapeutic strategies aimed at increasing HbF levels and their implications for the management of sickle cell disease.[58-60] Hydroxyurea is a cornerstone

treatment for sickle cell disease that has been shown to effectively stimulate the production of fetal hemoglobin. The exact mechanism by which hydroxyurea increases HbF levels is not fully understood, but it is believed to involve the induction of nitric oxide (NO) production, which can enhance erythropoiesis and promote HbF synthesis. Clinical studies have demonstrated that hydroxyurea therapy significantly reduces the frequency of vaso-occlusive crises, acute chest syndrome, and hospitalizations. Additionally, it is associated with improved overall health and quality of life in patients with sickle cell anemia. Hydroxyurea is generally well-tolerated, though potential side effects, such as myelosuppression, require careful monitoring.[61-63] Regular blood transfusions can effectively increase HbF levels by introducing normal red blood cells into circulation. This strategy reduces the proportion of sickled cells, leading to improved oxygen delivery to tissues and a decreased risk of vaso-occlusion. Blood transfusions are particularly beneficial in acute settings, such as during severe VOC or acute chest syndrome. However, long-term transfusion therapy poses risks, including iron overload, alloimmunization, and transfusion-related complications. As a result, patients receiving chronic transfusions require regular monitoring of iron levels and may benefit from iron chelation therapy to prevent iron overload.[64]
Gene editing techniques (e.g., CRISPR/Cas9) aim to correct the underlying genetic defect in the β-globin gene or reactivate fetal globin gene expression. By directly targeting the mutations responsible for sickle cell anemia or enhancing HbF production, gene editing holds the potential for curative treatment options.[65] Lentiviral vector-based gene transfer nvolves the use of lentiviral vectors to deliver therapeutic genes to hematopoietic stem cells (HSCs). By introducing a functional copy of the β-globin gene or genes that promote HbF synthesis, this strategy aims to produce genetically modified cells that can generate increased levels of HbF. Early clinical trials have shown promising results, with some patients achieving sustained increases in HbF levels following gene therapy.[66-67] For example, the consumption of foods rich in folate, vitamin B12, and vitamin C is essential for optimal erythropoiesis and may support HbF synthesis. Additionally, compounds like curcumin and resveratrol have been studied for their potential to enhance HbF levels through various molecular pathways. While these dietary interventions are not yet established therapies, they may provide adjunctive benefits when combined with standard treatments.[68-69]
Hematopoietic stem cell transplantation (HSCT) has the potential to cure sickle cell disease by replacing the patient's defective HSCs with healthy ones from a compatible donor. Successful transplantation can lead to the production of normal red blood cells, including HbF, effectively resolving the underlying genetic defect. Although HSCT is the only curative approach available, it is limited by the availability of matched donors and carries risks, including graft-versus-host disease (GVHD) and other complications. Ongoing research aims to refine transplantation techniques and expand access to this potentially curative therapy.[70] Investigating the role of transcription factors that regulate fetal globin gene expression may provide insights into novel therapeutic strategies. For instance, the reactivation of fetal globin genes can be influenced by factors such as BCL11A, which represses fetal hemoglobin production in adulthood. Targeting such transcription factors through small molecules or gene-editing techniques could enhance HbF synthesis and offer new therapeutic avenues for managing sickle cell disease.[69] Given the role of chronic inflammation in sickle cell disease, immune modulation and anti-inflammatory therapies may indirectly contribute to increased HbF levels. Therapies targeting inflammatory pathways, such as corticosteroids or biologics, may help reduce the overall inflammatory burden, thereby

creating a more favorable environment for HbF production. Research is ongoing to explore the effects of such therapies on HbF levels and clinical outcomes in sickle cell disease. Increasing HbF levels may also be supported through comprehensive patient education and supportive care. Encouraging patients to adhere to prescribed treatments, maintain a healthy lifestyle, and engage in regular medical follow-up can enhance overall management. Support groups and educational resources can empower patients to actively participate in their care and facilitate better outcomes.[70]

Conclusion

Fetal hemoglobin (HbF) plays a crucial role in modulating the pathophysiology of sickle cell anemia (SCA) by inhibiting sickle hemoglobin polymerization, enhancing red blood cell deformability, reducing blood viscosity, and modulating inflammatory responses. Understanding these protective mechanisms highlights the significance of HbF as a therapeutic target in managing sickle cell disease, particularly in reducing the frequency and severity of vaso-occlusive crises. The therapeutic strategies to increase HbF levels, including hydroxyurea therapy, blood transfusions, novel pharmacological agents, gene therapy, and dietary interventions, offer promising avenues for improving patient outcomes. Each approach presents unique benefits and challenges, underscoring the need for personalized treatment plans that consider individual patient factors, preferences, and potential complications. As research continues to advance, innovative therapies that effectively enhance HbF production and its protective effects are being explored, paving the way for improved management of sickle cell anemia.

References

1. Alenzi FQ, AlShaya DS. Biochemical and molecular analysis of the beta-globin gene on Saudi sickle cell anemia. Saudi Journal of Biological Sciences. 2019;26(7):1377-1384.
2. Williams TN, Thein SL. Sickle cell anemia and its phenotypes. Annual review of genomics and human genetics. 2018;19(1):113-147.
3. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
4. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
5. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
6. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
7. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
8. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-158.
9. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-2487.
10. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
11. Gkaliagkousi E, Ritter J, Ferro A. Platelet-derived nitric oxide signaling and regulation. Circulation research. 2007 Sep 28;101(7):654-662.

12. Tran N, Garcia T, Aniqa M, Ali S, Ally A, Nauli SM. Endothelial nitric oxide synthase (eNOS) and the cardiovascular system: in physiology and in disease states. American journal of biomedical science & research. 2022;15(2):153.
13. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-0487.
14. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
15. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
16. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
17. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
18. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13.
19. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
20. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-234.
21. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
22. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
23. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
24. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
25. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology. 2024;2(3):67-80.
26. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).
27. Vilas-Boas W, Cerqueira BA, Zanette AM, Reis MG, Barral-Netto M, Goncalves MS. Arginase levels and their association with Th17-related cytokines, soluble adhesion molecules (sICAM-1 and sVCAM-1) and hemolysis markers among steady-state sickle cell anemia patients. Annals of hematology. 2010; 89:877-882.
28. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-265.

29. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
30. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
31. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023; 6 (2): 10-13.
32. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
33. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
34. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
35. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
36. Tsikas D. Does the inhibitory action of asymmetric dimethylarginine (ADMA) on the endothelial nitric oxide synthase activity explain its importance in the cardiovascular system? The ADMA paradox. Journal of Controversies in Biomedical Research. 2017;3(1):16-22.
37. Martins R, Knapp S. Heme and hemolysis in innate immunity: adding insult to injury. Current opinion in immunology. 2018; 50:14-20.
38. Wu G, Meininger CJ, McNeal CJ, Bazer FW, Rhoads JM. Role of L-arginine in nitric oxide synthesis and health in humans. Amino acids in nutrition and health: Amino acids in gene expression, metabolic regulation, and exercising performance. 2021:167-87.
39. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
40. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
41. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
42. Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:58-66.

43. Roberts BW, Mitchell J, Kilgannon JH, Chansky ME, Trzeciak S. Nitric oxide donor agents for the treatment of ischemia/reperfusion injury in human subjects: a systematic review. Shock. 2013;39(3):229-339.
44. Obeagu EI, Obeagu GU. Addressing Myths and Stigmas: Breaking Barriers in Adolescent Sickle Cell Disease Education. Elite Journal of Health Science. 2024;2(2):7-15.
45. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine. 2024 Feb 9;103(6):e37127.
46. Obeagu EI. Chromium VI: A Silent Aggressor in Sickle Cell Anemia Pathophysiology. Elite Journal of Haematology, 2024; 2 (3).:81-95.
47. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
48. Samidurai A, Xi L, Das A, Kukreja RC. Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders. Annual review of pharmacology and toxicology. 2023;63(1):585-615.
49. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine. 2024;103(2):e36898.
50. Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. Elite Journal of Health Science. 2024;2(2):1-9.
51. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine. 2024;2(1):47-56.
52. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).
53. Obeagu EI, Obeagu GU. Synergistic Care Approaches: Integrating Diabetes and Sickle Cell Anemia Management. Elite Journal of Scientific Research and Review. 2024;2(1):51-64.
54. Grzywa TM, Sosnowska A, Matryba P, Rydzynska Z, Jasinski M, Nowis D, Golab J. Myeloid cell-derived arginase in cancer immune response. Frontiers in immunology. 2020; 11:938.
55. Obeagu EI, Obeagu GU. Improving Outcomes: Integrated Strategies for Diabetes and Sickle Cell Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):20-9.
56. Obeagu EI, Obeagu GU. The Role of Parents: Strengthening Adolescent Education for Sickle Cell Disease Prevention. Elite Journal of Public Health. 2024;2(1):15-21.
57. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:67-80.
58. Obeagu EI, Obeagu GU. Overcoming Hurdles: Anemia Management in Malaria-Affected Childhood. Elite Journal of Laboratory Medicine. 2024;2(1):59-69.
59. Bontempo P, Capasso L, De Masi L, Nebbioso A, Rigano D. Therapeutic Potential of Natural Compounds Acting through Epigenetic Mechanisms in Cardiovascular Diseases: Current Findings and Future Directions. Nutrients. 2024;16(15):2399.
60. Cao M, Zhao Y, He H, Yue R, Pan L, Hu H, Ren Y, Qin Q, Yi X, Yin T, Ma L. New applications of HBOC-201: a 25-year review of the literature. Frontiers in Medicine. 2021; 8:794561.

61. Brun M, Bourdoulous S, Couraud PO, Elion J, Krishnamoorthy R, Lapoumeroulie C. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. The Pharmacogenomics Journal. 2003;3(4):215-226.
62. Obeagu EI. Redox Signaling and Vaso-Occlusive Crisis in Sickle Cell Anemia. *Elite Journal of Haematology, 2024; 2(7):* 26-35
63. Obeagu EI. Hypoxia-Induced Signaling in the Pathogenesis of Vaso-Occlusive Crisis. *Elite Journal of Haematology, 2024; 2(7):* 36-43
64. Obeagu EI. Neurovascular Regulation and Vaso-Occlusive Crisis in Sickle Cell Disease. Elite Journal of Medicine, 2024; 2(7): 41-48
65. Obeagu EI. Bone Marrow Microenvironment and Vaso-Occlusive Crisis in Sickle Cell Disease. Elite Journal of Medicine, 2024; 2(7): 49-56
66. Obeagu EI. Role of G6PD Deficiency in Vaso-Occlusive Phenomena in Sickle Cell Disease. Elite Journal of Medical Sciences, 2024; 2(7):49-57
67. Obeagu EI. Role of the Reticuloendothelial System in Sickle Cell Vaso-Occlusion. Elite Journal of Medical Sciences, 2024; 2(7):58-65
68. Obeagu EI. Role of Myeloid-Derived Suppressor Cells in Vaso-Occlusive Crisis. Elite Journal of Health Science, 2024; 2(7): 28-35
69. Obeagu EI. Complement System Activation in Vaso-Occlusive Crisis of Sickle Cell Anemia. Elite Journal of Health Science, 2024; 2(7): 36-43
70. Obeagu EI. Hemorheology and Blood Flow Abnormalities in Sickle Cell Vaso-Occlusion. *Elite Journal of Scientific Research and Review*, 2024; 2(5): 14-24